This article is more than 5 years old. Information may no longer be current.
Patent allowance issued for glyceollin as diabetes, obesity therapy
Click Here to Manage Email Alerts
A notice of allowance for a MicroBiome Therapeutics LLC patent application covering the use of glyceollin for treatment of diabetes and obesity was recently issued by the US Patent and Trademark Office, according to a company press release. An allowance notice signifies that a patent application has survived the opposition period before finalization.
The treatment of metabolic disorders using glyceollins as well as a potential role in modulating the gastrointestinal microbiome is being investigated by MicroBiome Therapeutics.
Animal studies have revealed that glyceollins show activity in some human disease models, including breast and ovarian cancer, hypercholesterolemia and metabolic disorders. According to the release, glyceollin I, II and III are natural products made by soy plants that can help fight infectious organisms and other stressors.
“[MicroBiome Therapeutics] researchers have been studying glyceollins for some time, and we are excited about their potential as novel agents for the treatment of diabetes and obesity,” Steve Orndoff, PhD, CEO of MicroBiome Therapeutics, said in the release. “We are encouraged too by the results of our recently completed animal studies assessing whether glyceollin can affect the regulation of blood glucose, and we look forward to reporting the findings in a peer-reviewed forum. We also plan to study glyceollins as part of our gastrointestinal microbiome modulator (GIMM) program, whose lead products NM 504 and NM 505, have demonstrated positive results in pilot clinical studies in diabetes and prediabetes. With the broad claims of this new patent now assured, we intend to move ahead with this promising new approach to these conditions that adversely impact millions of people worldwide.”